Lilly's Bamlanivimab (LY-CoV555) Receives the US FDA's EUA for the Treatment of Recently Diagnosed COVID-19
Shots:
- The EUA is based on P-II BLAZE-1 study assessing bamlanivimab (700/2800/7000 mg) as monothx. vs PBO or in combination with second Ab for the treatment of symptomatic COVID-19 in the outpatient setting. The EUA is granted for bamlanivimab (LY-CoV555- 700 mg)
- Patients showed reduced viral load & rates of symptoms & hospitalization. The EUA includes a warning for hypersensitivity including anaphylaxis and infusion-related reactions
- The US government will allocate 300-000 doses of bamlanivimab to high-risk patients- with no out-of-pocket costs for the medication. Bamlanivimab should be administered asap after a positive COVID-19 test and within 10 days of symptom onset
Ref: Eli Lilly | Image: Business Standard
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com